Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Renal Cancer Therapy

Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6328-3

Synonyms

Definition

Therapy of nonmetastatic renal cancer is often based on surgical tumor removal with curative intention. In contrast, therapy of metastatic renal cancer is based on systemic therapy and aims to prolong survival and/or improve symptoms to maintain quality of life.

Characteristics

Almost 3 % of all malignant tumors in adults are renal cancers. In 2008, there were 54,390 new cases and 13,010 deaths from renal cancer and renal pelvis cancer in the US. The incidence of renal cancer – at least in the Western world – is rising. At primary diagnosis, most patients are 60–70 years old. The male to female ratio is 1.6:1. Renal cancers are organ confined in 55 %, locally advanced in 19 %, and associated with distant metastasis in 20 % of patients. The most frequent histologic subtype of renal cancer is clear cell (70 %) followed by papillary type 1 and 2 (10 %) and chromophobe (5–10 %) (renal cancer genetic syndromes)....

Keywords

Radiofrequency Ablation Active Surveillance Renal Cancer Radical Nephrectomy Watchful Waiting 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access

References

  1. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG (2006) The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 175(2):425–431CrossRefPubMedGoogle Scholar
  2. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 1:CD001425PubMedGoogle Scholar
  3. Coppin C, Le L, Porzsolt F, Wilt T (2008) Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 2:CD006017PubMedGoogle Scholar
  4. Halbert RJ, Figlin RA, Atkins MB, Bernal M, Hutson TE, Uzzo RG, Bukowski RM, Khan KD, Wood CG, Dubois RW (2006) Treatment of patients with metastatic renal cell cancer: a RAND appropriateness panel. Cancer 107(10):2375–2383CrossRefPubMedGoogle Scholar
  5. Kunkle DA, Egleston BL, Uzzo RG (2008) Excise, ablate or observe: the small renal mass dilemma–a meta-analysis and review. J Urol 179(4):1227–1233CrossRefPubMedGoogle Scholar
  6. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ, Sinescu IC (2007) European Association of Urology Guideline Group for renal cell carcinoma. Renal cell carcinoma guideline. Eur Urol 51(6):1502–1510CrossRefPubMedGoogle Scholar
  7. Rini BI, Bukowski RM (2008) Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress? Oncology (Williston Park) 22(4):388–396Google Scholar

See Also

  1. (2012) Cryoablation. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1001. doi: 10.1007/978-3-642-16483-5_6503Google Scholar
  2. (2012) Embolization. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1220. doi: 10.1007/978-3-642-16483-5_1856Google Scholar
  3. (2012) Interleukin-2. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1892. doi: 10.1007/978-3-642-16483-5_3097Google Scholar
  4. (2012) Ipsilateral. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1909. doi: IpsilateralGoogle Scholar
  5. (2012) Monoclonal Antibody. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2367. doi: 10.1007/978-3-642-16483-5_6842Google Scholar
  6. (2012) Monoclonal Antibody Therapy. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, pp 2367–2368. doi: 10.1007/978-3-642-16483-5_3823Google Scholar
  7. (2012) Motzer Criteria. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2377. doi: 10.1007/978-3-642-16483-5_6494Google Scholar
  8. (2012) Pazopanib. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2799. doi: 10.1007/978-3-642-16483-5_6694Google Scholar
  9. (2012) Prognosis. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2994. doi: 10.1007/978-3-642-16483-5_4758Google Scholar
  10. (2012) Progression-Free Survival. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3001. doi: 10.1007/978-3-642-16483-5_6496Google Scholar
  11. (2012) Radiotherapy. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3158. doi: 10.1007/978-3-642-16483-5_4926Google Scholar
  12. (2012) Sunitinib. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3562. doi: 10.1007/978-3-642-16483-5_5575Google Scholar
  13. (2012) Systemic Therapy. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3598. doi: 10.1007/978-3-642-16483-5_5641Google Scholar
  14. (2012) T Cell. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 3599. doi: 10.1007/978-3-642-16483-5_5645Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Urologikum LübeckLübeckGermany
  2. 2.Department of UrologyUniversity of Luebeck, Medical SchoolLuebeckGermany